To read the full story, subscribe or sign in.

Tragara Pays $112M to Jointly Develop S*BIO Compound

Jan. 22, 2009

Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...